What is the first-line antihypertensive medication for a patient with suspected heart failure?

First-Line Antihypertensive for Suspected Heart Failure

For a patient with suspected heart failure, initiate an ACE inhibitor (or ARB if ACE inhibitor intolerant) combined with a beta-blocker as first-line antihypertensive therapy, regardless of blood pressure level. These agents are the cornerstone of heart failure management and provide mortality benefit while simultaneously controlling hypertension 1, 2, 3, 4.

Treatment Algorithm

Step 1: Initiate ACE Inhibitor

• Start low, go slow: Begin with low doses (e.g., enalapril 2.5 mg twice daily, lisinopril 2.5-5 mg daily, or ramipril 2.5 mg daily) 2, 5
• Target doses: Titrate to evidence-based targets (enalapril 10-20 mg twice daily, lisinopril 20-40 mg daily, ramipril 10 mg daily) 1, 2
• If ACE inhibitor intolerant (typically due to cough or angioedema): Substitute an ARB (candesartan 4-8 mg daily targeting 32 mg daily, or valsartan 40 mg twice daily targeting 160 mg twice daily) 2, 5

Step 2: Add Beta-Blocker

• Proven agents only: Use bisoprolol (1.25 mg daily → 10 mg daily), carvedilol (3.125 mg twice daily → 25-50 mg twice daily), or metoprolol succinate (12.5-25 mg daily → 200 mg daily) 1, 2, 3
• Timing: Can be initiated simultaneously with ACE inhibitor or sequentially, without waiting for ACE inhibitor target dose 6, 1
• Both classes reduce mortality by approximately 34% and hospitalizations by 28-36% 5

Step 3: Add Diuretics for Congestion

• Loop diuretics (furosemide 20-40 mg once or twice daily, bumetanide 0.5-1 mg, or torsemide 10-20 mg) are recommended for fluid retention symptoms 2, 5
• Always administered in addition to ACE inhibitor, never as monotherapy 7
• Diuretics improve symptoms but do not reduce mortality

Step 4: Consider Aldosterone Antagonist

• Add spironolactone (12.5-25 mg daily → 25-50 mg daily) if patient remains symptomatic (NYHA class II-IV) despite ACE inhibitor and beta-blocker 1, 2, 3
• Critical safety monitoring: Potassium must be <5.0 mEq/L and creatinine ≤2.5 mg/dL in men or ≤2.0 mg/dL in women before initiation 2
• Check potassium and renal function at 1 week, then regularly 7, 2

Modern Considerations

ARNI (Sacubitril/Valsartan)

For established HFrEF, consider switching from ACE inhibitor to sacubitril/valsartan (starting 24/26-49/51 mg twice daily → 97/103 mg twice daily) once diagnosis is confirmed, as it provides superior blood pressure control and mortality reduction compared to ACE inhibitors 1, 8. However, for initial management of suspected heart failure, start with traditional ACE inhibitor/beta-blocker combination.

SGLT2 Inhibitors

Add dapagliflozin 10 mg or empagliflozin 10 mg daily once heart failure is confirmed, as these provide additional mortality and hospitalization benefits across the ejection fraction spectrum 1, 9, 10.

Critical Monitoring Parameters

Within 1-2 weeks of initiation or dose changes, check:

• Blood pressure (target <140/90 mm Hg, but <130/80 mm Hg if diabetic or CKD) 2, 11
• Renal function (creatinine increase up to 50% or to 265 μmol/L [3 mg/dL] is acceptable) 5
• Potassium (maintain ≥4.0 mEq/L but <5.5 mEq/L) 7, 5

Common Pitfalls to Avoid

1. Do NOT use calcium channel blockers (diltiazem, verapamil) as they worsen heart failure outcomes 3
2. Do NOT use alpha-blockers (doxazosin) as first-line agents—they increase mortality 12, 11
3. Do NOT withhold beta-blockers due to low blood pressure unless symptomatic—adjust other medications first 6
4. Do NOT delay beta-blocker initiation until ACE inhibitor is at target dose 6, 1
5. Do NOT use thiazides if GFR <30 mL/min—use loop diuretics instead 7

Special Populations

If patient cannot tolerate ACE inhibitor or ARB (due to renal dysfunction or hyperkalemia), consider hydralazine-isosorbide dinitrate combination (hydralazine 37.5 mg three times daily → 75 mg three times daily plus isosorbide dinitrate 20 mg three times daily → 40 mg three times daily), though evidence is weaker 1, 4.

For African American patients with persistent symptoms, add hydralazine-isosorbide dinitrate to standard therapy for additional mortality benefit 4.

This approach prioritizes medications with proven mortality benefit while simultaneously controlling blood pressure, addressing both conditions with a unified, evidence-based strategy.